Cargando…

Use of lacosamide in children: experience of a tertiary medical care center in Brazil

Background  Lacosamide (LCM) is a third-generation anti-seizure drug approved in Europe and the United States, either as a monotherapy or adjunctive therapy, to treat partial-onset seizures in adults, adolescents, and children. In Brazil, LCM is licensed for treatment only in patients older than 16...

Descripción completa

Detalles Bibliográficos
Autores principales: Romão, Tayla Taynan, Angelim, Abraão Iuri Medeiros, Prado, Henrique Jannuzzelli Pires do, Goes, Fernanda Veiga de, Pires, Maria Elisa Paiva, Fontana, Rosiane da Silva, Pires, Lais de Carvalho, Fernandes, Alexandre Ribeiro, D'Andrea-Meira, Isabella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Revinter Publicações Ltda. 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797266/
https://www.ncbi.nlm.nih.gov/pubmed/36577407
http://dx.doi.org/10.1055/s-0042-1758366
_version_ 1784860655511142400
author Romão, Tayla Taynan
Angelim, Abraão Iuri Medeiros
Prado, Henrique Jannuzzelli Pires do
Goes, Fernanda Veiga de
Pires, Maria Elisa Paiva
Fontana, Rosiane da Silva
Pires, Lais de Carvalho
Fernandes, Alexandre Ribeiro
D'Andrea-Meira, Isabella
author_facet Romão, Tayla Taynan
Angelim, Abraão Iuri Medeiros
Prado, Henrique Jannuzzelli Pires do
Goes, Fernanda Veiga de
Pires, Maria Elisa Paiva
Fontana, Rosiane da Silva
Pires, Lais de Carvalho
Fernandes, Alexandre Ribeiro
D'Andrea-Meira, Isabella
author_sort Romão, Tayla Taynan
collection PubMed
description Background  Lacosamide (LCM) is a third-generation anti-seizure drug approved in Europe and the United States, either as a monotherapy or adjunctive therapy, to treat partial-onset seizures in adults, adolescents, and children. In Brazil, LCM is licensed for treatment only in patients older than 16 years of age. Objective  To evaluate a cohort of children presenting with refractory epilepsy who received LCM as an add-on therapy and observe the response and tolerability to the LCM treatment. Methods  A retrospective cohort study conducted in a tertiary health care facility, which included 26 children, aged up to 16 years, who presented with refractory epilepsy and received LCM as an add-on treatment. The follow-up visits were scheduled every 3 months until 9 months of treatment with LCM. Results  After 3 months of LCM administration, in 73.1% of the children, there was a reduction of > 50% in the frequency of seizures, and this clinical improvement was maintained in most patients (73.9%) for the following 9 months. Mild (such as, somnolence and behavioral changes) or severe (seizure worsening) adverse effects were observed in two and three children respectively. Among responders to LCM, there was a higher prevalence of males, fewer concomitant anti-seizure drugs, and lower percentage of patients using sodium channel blockers. Conclusions  Lacosamide should be considered as an early treatment option in pediatric patients with refractory epilepsy, mainly focal seizures.
format Online
Article
Text
id pubmed-9797266
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Thieme Revinter Publicações Ltda.
record_format MEDLINE/PubMed
spelling pubmed-97972662023-01-09 Use of lacosamide in children: experience of a tertiary medical care center in Brazil Romão, Tayla Taynan Angelim, Abraão Iuri Medeiros Prado, Henrique Jannuzzelli Pires do Goes, Fernanda Veiga de Pires, Maria Elisa Paiva Fontana, Rosiane da Silva Pires, Lais de Carvalho Fernandes, Alexandre Ribeiro D'Andrea-Meira, Isabella Arq Neuropsiquiatr Background  Lacosamide (LCM) is a third-generation anti-seizure drug approved in Europe and the United States, either as a monotherapy or adjunctive therapy, to treat partial-onset seizures in adults, adolescents, and children. In Brazil, LCM is licensed for treatment only in patients older than 16 years of age. Objective  To evaluate a cohort of children presenting with refractory epilepsy who received LCM as an add-on therapy and observe the response and tolerability to the LCM treatment. Methods  A retrospective cohort study conducted in a tertiary health care facility, which included 26 children, aged up to 16 years, who presented with refractory epilepsy and received LCM as an add-on treatment. The follow-up visits were scheduled every 3 months until 9 months of treatment with LCM. Results  After 3 months of LCM administration, in 73.1% of the children, there was a reduction of > 50% in the frequency of seizures, and this clinical improvement was maintained in most patients (73.9%) for the following 9 months. Mild (such as, somnolence and behavioral changes) or severe (seizure worsening) adverse effects were observed in two and three children respectively. Among responders to LCM, there was a higher prevalence of males, fewer concomitant anti-seizure drugs, and lower percentage of patients using sodium channel blockers. Conclusions  Lacosamide should be considered as an early treatment option in pediatric patients with refractory epilepsy, mainly focal seizures. Thieme Revinter Publicações Ltda. 2022-12-28 /pmc/articles/PMC9797266/ /pubmed/36577407 http://dx.doi.org/10.1055/s-0042-1758366 Text en Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit ( https://creativecommons.org/licenses/by/4.0/ ) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Romão, Tayla Taynan
Angelim, Abraão Iuri Medeiros
Prado, Henrique Jannuzzelli Pires do
Goes, Fernanda Veiga de
Pires, Maria Elisa Paiva
Fontana, Rosiane da Silva
Pires, Lais de Carvalho
Fernandes, Alexandre Ribeiro
D'Andrea-Meira, Isabella
Use of lacosamide in children: experience of a tertiary medical care center in Brazil
title Use of lacosamide in children: experience of a tertiary medical care center in Brazil
title_full Use of lacosamide in children: experience of a tertiary medical care center in Brazil
title_fullStr Use of lacosamide in children: experience of a tertiary medical care center in Brazil
title_full_unstemmed Use of lacosamide in children: experience of a tertiary medical care center in Brazil
title_short Use of lacosamide in children: experience of a tertiary medical care center in Brazil
title_sort use of lacosamide in children: experience of a tertiary medical care center in brazil
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797266/
https://www.ncbi.nlm.nih.gov/pubmed/36577407
http://dx.doi.org/10.1055/s-0042-1758366
work_keys_str_mv AT romaotaylataynan useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil
AT angelimabraaoiurimedeiros useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil
AT pradohenriquejannuzzellipiresdo useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil
AT goesfernandaveigade useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil
AT piresmariaelisapaiva useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil
AT fontanarosianedasilva useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil
AT pireslaisdecarvalho useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil
AT fernandesalexandreribeiro useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil
AT dandreameiraisabella useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil